Combining the monoclonal anti-VEGF antibody bevacizumab with carboplatin/paclitaxel resulted in longer survival time compared with chemotherapy treatment alone in patients with non–small-cell lung cancer (NSCLC) [6]. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.